Results 191 to 200 of about 284,370 (314)

AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. [PDF]

NPJ Precis Oncol
Ishida M, Yamada T, Katayama Y, Kawachi H, Sawada R, Nakamura R, Hirai S, Matsui Y, Morimoto K, Onoi K, Nakamura-Sasada A, Horinaka M, Sakai T, Sakakida T, Doi T, Yasumoto K, Goto Y, Furuya N, Taniguchi H, Ogino H, Takayuki N, Chihara Y, Fukuda K, Taniguchi H, Uehara H, Yano S, Tokuda S, Takayama K.   +27 more
europepmc   +1 more source

MUC1 as a Survival Effector of Radiotherapy‐Induced Epithelial Hybrid States in Basal‐Like Breast Cancer

International Journal of Cancer, EarlyView.
Basal‐like breast cancer (BLBC) is aggressive and often exhibits inherent or acquired resistance to radiotherapy (RT), a primary treatment option. RT resistance is underpinned by molecular alterations, many of which are poorly understood. Here, RT‐induced transcriptomic changes were analyzed using bulk and spatial sequencing in a BLBC mouse model and ...
Garyfallia Pantelaiou‐Prokaki, Husam Bamahmoud, Nadine S. Georges, Shaishavi Jansari, Annika Jung, Daniela Grimm, Evangelos Prokakis, Fabian Alexander Gayer, Maryam Deldar, Christian Dullin, Julia Gallwas, Florian Wegwitz, Frauke Alves   +12 more
wiley   +1 more source

Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer. [PDF]

NPJ Breast Cancer
Van Mackelenbergh MT, Pfarr N, Weber K, Untch M, Solbach C, Schneeweiss A, Jank P, Blohmer J, Treue D, Schmatloch S, Lehmann A, Hanusch C, Link T, Sers C, Bjelic-Radisic V, Hummel M, Huober J, Schmitt WD, Fasching PA, Aktas B, Rhiem K, Reinisch M, Nekljudova V, Denkert C, Loibl S.   +24 more
europepmc   +1 more source

The Predictive Value of the Tumor‐Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor‐Positive Breast Cancer

International Journal of Cancer, EarlyView.
Neoadjuvant endocrine therapy (NET) can help prevent metastases and improve survival in patients with hormone receptor‐positive (HR+) breast cancer. Identifying which HR+ patients will benefit from NET, however, remains challenging. Here, in a patient cohort in the Netherlands, the authors evaluated tumor‐stroma ratio (TSR) and magnetic resonance ...
Layla Andour, Sophie C. Hagenaars, Anne Florine de Groot, Elly M. M. Krol‐Warmerdam, Judith R. Kroep, Hans Marten Hazelbag, Gerrit‐Jan Liefers, Marieke E. Straver, Wilma E. Mesker   +8 more
wiley   +1 more source

Elucidating the relationship between affinity and potency in the performance of therapeutic IgE. [PDF]

Sci Rep
Marano F, McKenzie C, Birtley JR, Hussain SA, Macleod O, Goodacre A, Wu S, Amin OE, Faulkner N, Devlin J, Regan L, Soni K, Johnson RM, Pye VE, Wilson T, Hardaker E, FitzGerald K.   +16 more
europepmc   +1 more source

Generation of Allogeneic CAR‐T Circumvents Functional Deficits in Patient‐Derived Autologous Product for Glioblastoma

International Journal of Cancer, EarlyView.
Clinical trials of chimeric antigen receptor T‐cell (CAR‐T) therapies in glioblastoma have shown limited clinical benefits. Whether this may be explained by the basal quality of CAR‐T products, which are currently generated using patient, autologous T‐cells, has been little explored.
Sabra K. Salim, Muhammad Vaseem Shaikh, Jeffrey Wei, William T. Maich, Alisha Anand, Oliver Y. Tang, Minomi K. Subapanditha, Zahra Alizada, Yujin Suk, Manoj Singh, Kui Zhai, Aapti Khanna, Benjamin Brakel, Vassil Dimitrov, Zoya Tabunshchyk, Katie Chan, Kevin R. Brown, Parvez Vora, Donald M. O'Rourke, Zev A. Binder, Chitra Venugopal, Jason Moffat, Sheila K. Singh   +22 more
wiley   +1 more source

Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial

International Journal of Cancer, EarlyView.
Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...
Manuel Hörner, Henning Schäffler, Lothar Häberle, Chloë Goossens, Kerstin Pfister, Elena Leinert, Kristina Veselinovic, Sara Y. Brucker, Uwe Köhler, Georg Heinrich, Andreas Schneeweiss, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Brigitte Rack, Sabine Heublein, Philipp Ziegler   +16 more
wiley   +1 more source

Multi-site validation of an AI-based biomarker test for determining ER, PR, and HER2 status from H&E-stained breast cancer slides. [PDF]

ESMO Real World Data Digit Oncol
Ntelemis F, Wolf S, Bass C, Geraldes A, Schmidt J, Kumar N, Singhal S, Mehrotra D, Marcia A, Blackwood J, Maiques O, Ironside A, Staves JJ, Leff D, Um IH, Loane J, Bryson G, Harrison DJ, Khurram SA, Spary L, Clarkson R, Kather JN, Pandya P, Arslan S.   +23 more
europepmc   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source

Influence of Peptide-Based Chelator Sequences on HER2-Targeting Radiopeptide. [PDF]

J Pept Sci
Gupta S, Kumar M, Repaka KM, Das A, Kengar AA, Satpati D.   +5 more
europepmc   +1 more source